- Aethlon Medical ( NASDAQ: AEMD ) said it signed an agreement with a MedTech Contract Research Organization (CRO) called NAMSA to oversee the company's clinical trials of immunotherapeutic device Hemopurifier for oncology indications.
- Under the agreement, NAMSA will manage Aethlon's study of the Hemopurifier for patients in the U.S. and Australia with various types of cancer tumors. The company expects initial trials will start in Australia.
- "We are extremely pleased that Aethlon selected NAMSA as their strategic outsourcing partner for their clinical research program," said NAMSA CEO Christophe Berthoux.
- AEMD +38.30% to $0.65 premarket Jan. 30
For further details see:
Aethlon stock soars ~40% on pact for Hemopurifier clinical program in cancer